A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Sponsors Pharmacyclics
- 17 Nov 2017 Status changed from active, no longer recruiting to completed.
- 29 Sep 2017 Planned End Date changed from 1 Nov 2018 to 1 Nov 2017
- 27 Sep 2017 Planned End Date changed from 1 Apr 2018 to 1 Nov 2018.